Brokerages Set The Clorox Company (NYSE:CLX) PT at $155.00

The Clorox Company (NYSE:CLX) has earned an average recommendation of “Reduce” from the fifteen research firms that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $155.00.

Several equities analysts have recently issued reports on the company. BNP Paribas upgraded Clorox to a “strong sell” rating in a research report on Friday, September 6th. TD Cowen raised shares of Clorox from a “sell” rating to a “hold” rating and raised their target price for the company from $155.00 to $170.00 in a research note on Wednesday, November 6th. Evercore ISI reduced their price target on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating for the company in a research note on Monday, October 14th. Barclays increased their price objective on shares of Clorox from $137.00 to $139.00 and gave the company an “underweight” rating in a report on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Clorox from $144.00 to $151.00 and gave the stock a “hold” rating in a report on Friday, August 2nd.

Clorox Stock Down 0.6 %

Shares of NYSE:CLX opened at $168.16 on Wednesday. The firm has a market cap of $20.81 billion, a PE ratio of 58.59, a price-to-earnings-growth ratio of 3.10 and a beta of 0.41. Clorox has a 12-month low of $127.60 and a 12-month high of $169.21. The company has a fifty day simple moving average of $162.56 and a 200 day simple moving average of $147.94. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08.

Clorox (NYSE:CLX) last posted its earnings results on Wednesday, October 30th. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.36 by $0.50. Clorox had a return on equity of 316.08% and a net margin of 4.78%. The company had revenue of $1.76 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same period in the prior year, the company earned $0.49 earnings per share. The business’s revenue was up 27.0% compared to the same quarter last year. On average, equities research analysts anticipate that Clorox will post 6.85 EPS for the current fiscal year.

Clorox Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 29th will be issued a dividend of $1.22 per share. This represents a $4.88 dividend on an annualized basis and a dividend yield of 2.90%. Clorox’s dividend payout ratio is 170.04%.

Insider Buying and Selling

In other news, EVP Angela C. Hilt sold 1,733 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $165.52, for a total value of $286,846.16. Following the transaction, the executive vice president now owns 13,471 shares in the company, valued at $2,229,719.92. This represents a 11.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.57% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CLX. Prospera Private Wealth LLC acquired a new position in shares of Clorox in the third quarter worth $27,000. Continuum Advisory LLC grew its stake in Clorox by 300.0% in the third quarter. Continuum Advisory LLC now owns 184 shares of the company’s stock valued at $30,000 after purchasing an additional 138 shares in the last quarter. First Foundation Advisors acquired a new position in Clorox in the 1st quarter worth about $31,000. Innealta Capital LLC purchased a new stake in shares of Clorox during the 2nd quarter worth about $30,000. Finally, Trifecta Capital Advisors LLC lifted its holdings in shares of Clorox by 139.8% during the 2nd quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company’s stock valued at $30,000 after buying an additional 130 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.